Compare CDZIP & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CDZIP | IDYA |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | 25 | N/A |
| Industry | Water Supply | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 2.9B |
| IPO Year | N/A | 2019 |
| Metric | CDZIP | IDYA |
|---|---|---|
| Price | $19.63 | $34.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $49.42 |
| AVG Volume (30 Days) | N/A | ★ 1.0M |
| Earning Date | N/A | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $214,834,000.00 |
| Revenue This Year | N/A | $2,434.86 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 5377.66 |
| 52 Week Low | N/A | $13.45 |
| 52 Week High | N/A | $37.08 |
| Indicator | CDZIP | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 55.01 | 52.66 |
| Support Level | $19.51 | $33.11 |
| Resistance Level | $19.64 | $34.45 |
| Average True Range (ATR) | 0.14 | 1.38 |
| MACD | -0.00 | -0.31 |
| Stochastic Oscillator | 37.52 | 18.97 |
Cadiz Inc is a water solutions provider, dedicated to delivering clean, reliable, and affordable water for people. It provides water solutions with a combination of land, water, pipeline, and water filtration assets located in Southern California between key water systems serving population centers in the Southwestern United States. The company operates in two reportable segments; Land and Water Resources segment, which derives key revenue, and comprises all activities regarding its properties in the eastern Mojave Desert, pre-revenue development of the Mojave Groundwater Bank (supply, storage, and conveyance), and agricultural operations; and the Water Filtration Technology segment, which provides water filtration solutions for impaired or contaminated groundwater sources.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.